Circulation Journal
Arrhythmia/Electrophysiology
Effects of Intravenous Nifekalant as a Lifesaving Drug for Severe Ventricular Tachyarrhythmias Complicating Acute Coronary Syndrome
Satoru YusuTakanori IkedaHisaaki MeraMutsumi MiyakoshiYosuke MiwaAtsuko AbeTakehiro TsukadaHaruhisa IshiguroHisashi ShimizuHideaki Yoshino
Author information
JOURNALS FREE ACCESS

Volume 73 (2009) Issue 11 Pages 2021-2028

Details
Download PDF (432K) Contact us
Abstract

Background: Intravenous amiodarone (AMD) has been used for the treatment of ventricular tachycardia/fibrillation (VT/VF) in emergency care medicine. However, AMD acts slowly and is occasionally accompanied by hypotension and bradycardia. The antiarrhythmic effect of intravenous nifekalant (NIF) was assessed in patients with VT/VF complicating acute coronary syndrome (ACS) according to our study protocol. Methods and Results: Among a series of 1,143 ACS patients, 41 patients who suffered sustained VT/VF were enrolled; 19 failed to respond to a preceding lidocaine (LID) injection. NIF was given first as an intravenous bolus injection (0.2 mg/kg) and then as a continuous intravenous infusion at a relatively low dose level (0.2 mg · kg-1 · h-1). Sustained VT/VF was successfully inhibited by NIF in 34 patients (83%). In subgroup analysis, NIF achieved VT/VF inhibition in 79% of patients who received preceding LID and in 86% of patients who received direct NIF. There were no significant changes in systolic blood pressure or heart rate following NIF therapy. A corrected QT interval was significantly prolonged (P<0.01), whereas torsade de pointes developed in only 1 patient (2%). Conclusions: An intravenous bolus injection and subsequent continuous infusion of NIF at a relatively low dosage were effective in treating severe ventricular tachyarrhythmias complicating ACS, reducing the potential risk of proarrhythmia. (Circ J 2009; 73: 2021-2028)

Information related to the author
© 2009 THE JAPANESE CIRCULATION SOCIETY
Previous article Next article
feedback
Top